HCA reported solid Q2 2026 results with revenue of $20.23B and adjusted EPS of $7.59, topping estimates. The company reaffirmed 2026 guidance for EPS of $28.70-$30.50 and sales of $77B-$79.5B, signaling steady demand. The print triggered modest stock strength and likely upward revisions to some analysts' targets.
On July 14, 2026, HCA disclosed a substantial downgrade to FY2026 guidance due to a weaker payer mix from rising uninsured visits, lowering EPS to $28.70–$30.50 and revenue to $77–$79.5B, with EBITDA of $15.4–$16.1B. The stock closed down 6.95% to $363.60. Later, The Portnoy Law Firm announced a securities-fraud investigation, potentially adding litigation risk to an already challenged outlook.
HCA Healthcare posted strong Q1 results with a 4.3% revenue increase, aligning with expectations. The company reaffirmed its full-year earnings guidance, indicating stability in its financial outlook, which likely contributed to the 2.2% rise in share price.
HCA Healthcare reported stronger-than-expected Q1 profits, fueled by high demand for its medical services. This performance exceeded analysts' forecasts, potentially signaling robust revenue streams that could enhance investor sentiment moving forward.
HCA is set to release Q1 earnings on April 24, with analysts forecasting a solid increase in both earnings and revenue. The focus on dividends may attract investors seeking income opportunities, especially with a slight rise in share prices leading up to the earnings report.
HCA Healthcare's fourth-quarter 2025 earnings were mixed, indicating potential challenges in revenue growth and profitability. Investors should closely monitor the company's future guidance and operational efficiencies for further insights into its performance trajectory.